4Sadeque AJ, Fisher MB, Korzekwa KR,et al. Human CYP2C9 and CYP2A6 mediate formation of the hepatotoxin 4-ene-valproic acid [J]. J Pharmacol Exp Ther, 1997, 283: 698.
5Kiang TK, Ho PC, Anari MR, et al. Contribution of CYP2C9, CYP2A6, and CYP2B6 to valproic acid metabolism in hepatic microsomes from individuals with the CYP2C9 * 1/* 1 genotype [ J]. Toxicol Sci, 2006, 94:261.
7Koren G, Nava-Ocampo AA, Moretti ME, et al. Major malformations with valproic acid [ J]. Can Faro Physician, 2006, 52:441.
8Bauer J, Jarre A, Klingmuller D, et al. Polycystic ovary syndrome in patients with focal epilepsy: a study in 93 women [ J]. Epilepsy Res, 2000, 41 : 163.
9Devane CL. Pharmacokinetics, drug interactions, and tolerability of valproate [ J]. Psychopharmacol Bull, 2003, 37 ( Suppl 2) :S25.
10Hadidi H, Irshaid Y, Vagbo CB, et al. Variability of coumarin 7- and 3-hydroxylation in a Jordanian population is suggestive of a functional polymorphism in cytochrome P450 CYP2A6 [ J]. Eur J Clin Pharmacol, 1998, 54:437.
